October 2022 (Revised May 2023)
Case
HBS Case Collection

Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues

By: Aiyesha Dey, Jonas Heese, Suraj Srinivasan and Annelena Lobb

Format:Print
| Language:English
| Pages:29

Abstract

Ginkgo Bioworks, a synthetic biology company based in Boston, Massachusetts, faced divergent views on its revenue possibilities and accounting practices. After a report emerged accusing it of fraudulent accounting and lack of innovation, its share price plunged. But some investors saw this as a buying opportunity and still believed in Ginkgo’s prospects. Who was right?

Keywords

Fraud Allegations; Revenue; Reports; Accounting Audits; Innovation and Management; Investment; Biotechnology Industry; Boston

Citation

Dey, Aiyesha, Jonas Heese, Suraj Srinivasan, and Annelena Lobb. "Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues." Harvard Business School Case 123-037, October 2022. (Revised May 2023.)